GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ryvu Therapeutics SA (FRA:9Y4) » Definitions » Long-Term Debt

Ryvu Therapeutics (FRA:9Y4) Long-Term Debt : €18.09 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Ryvu Therapeutics Long-Term Debt?

Ryvu Therapeutics's Long-Term Debt for the quarter that ended in Dec. 2024 was €18.09 Mil.

Ryvu Therapeutics's quarterly Long-Term Debt increased from Jun. 2024 (€12.66 Mil) to Sep. 2024 (€17.71 Mil) and increased from Sep. 2024 (€17.71 Mil) to Dec. 2024 (€18.09 Mil).

Ryvu Therapeutics's annual Long-Term Debt stayed the same from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€0.00 Mil) but then increased from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€18.09 Mil).

Ryvu Therapeutics Long-Term Debt Historical Data

The historical data trend for Ryvu Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ryvu Therapeutics Long-Term Debt Chart

Ryvu Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.38 0.18 - - 18.09

Ryvu Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 6.37 12.66 17.71 18.09

Ryvu Therapeutics  (FRA:9Y4) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Ryvu Therapeutics Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Ryvu Therapeutics's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Ryvu Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ryvu Therapeutics SA (FRA:9Y4) » Definitions » Long-Term Debt
Comparable Companies
WAR:BCX WAR:BIO WAR:SVE WAR:MAB WAR:MOC WAR:PTG WAR:CTX WAR:URT WAR:NNG WAR:RDG VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
RVU:Poland 9Y4:Germany
Address
Leona Henryka Sternbacha 2, Krakow, POL, 30-394
Website
https://www.ryvu.com
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.

Ryvu Therapeutics Headlines

No Headlines